Drug Trial Radar · NCT04003857
Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial
Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 5, 2019
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Medipost Co Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 60 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT03392467) will be followed-up until 60 months of corrected age
Conditions
- Bronchopulmonary Dysplasia
- BPD
Interventions
PNEUMOSTEM®Biological
A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)
normal salineBiological
A single intratracheal administration of normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Respiratory outcome: Number of hospitalizationsTime frame: 6 months corrected age
- Respiratory outcome: Number of hospitalizationsTime frame: 12 months corrected age
- Respiratory outcome: Number of hospitalizationsTime frame: 18 months corrected age
- Respiratory outcome: Number of hospitalizationsTime frame: 24 months corrected age
- Respiratory outcome: Number of hospitalizationsTime frame: 36 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 39 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 42 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 45 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 48 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 51 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 54 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 57 months after birth
- Respiratory outcome: Number of hospitalizationsTime frame: 60 months after birth
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.